| Press releases

Formycon Reports Financial and Operating Results for the First Half Year of 2018

Formycon AG has revealed impressive results for the first half of 2018 both in the development of its product candidates and its business figures.


German Equity Forum

November 26 – 28, 2018; Frankfurt/Germany

Financial reports

Annual Report 2017

Published on:
May 7, 2018

  • Forschung_und_Entwicklung_2018_web_en
  • Teaser_mitglied-bio-deutschland-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out, one project has been transferred into a joint venture.